JPWO2020227325A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020227325A5
JPWO2020227325A5 JP2021565854A JP2021565854A JPWO2020227325A5 JP WO2020227325 A5 JPWO2020227325 A5 JP WO2020227325A5 JP 2021565854 A JP2021565854 A JP 2021565854A JP 2021565854 A JP2021565854 A JP 2021565854A JP WO2020227325 A5 JPWO2020227325 A5 JP WO2020227325A5
Authority
JP
Japan
Prior art keywords
amino
oxoindolin
dioxopiperidin
dioxoisoindolin
ylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021565854A
Other languages
Japanese (ja)
Other versions
JP2022531446A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031527 external-priority patent/WO2020227325A1/en
Publication of JP2022531446A publication Critical patent/JP2022531446A/en
Publication of JPWO2020227325A5 publication Critical patent/JPWO2020227325A5/ja
Pending legal-status Critical Current

Links

Claims (1)

ｇ． （Ｚ）－Ｎ－（３－（４－（５－（（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－４－イル）アミノ）ペンタノイル）ピペラジン－１－イル）プロピル）－５－（（５－フルオロ－２－オキソインドリン－３－イリデン）メチル）－２，４－ジメチル－１Ｈ－ピロール－３－カルボキサミド（ＨＣ５８－３８）；
ｈ． （Ｚ）－Ｎ－（３－（４－（２－（（５－（（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－４－イル）アミノ）ペンチル）アミノ）－２－オキソエチル）ピペラジン－１－イル）プロピル）－５－（（５－フルオロ－２－オキソインドリン－３－イリデン）メチル）－２，４－ジメチル－１Ｈ－ピロール－３－カルボキサミド（ＨＣ５８－７５）；
ｉ． （Ｚ）－Ｎ－（３－（４－（２－（（６－（（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－４－イル）アミノ）ヘキシル）アミノ）－２－オキソエチル）ピペラジン－１－イル）プロピル）－５－（（５－フルオロ－２－オキソインドリン－３－イリデン）メチル）－２，４－ジメチル－１Ｈ－ピロール－３－カルボキサミド（ＨＣ５８－７６）；および
ｊ． （Ｚ）－Ｎ－（３－（４－（２－（（８－（（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－４－イル）アミノ）オクチル）アミノ）－２－オキソエチル）ピペラジン－１－イル）プロピル）－５－（（５－フルオロ－２－オキソインドリン－３－イリデン）メチル）－２，４－ジメチル－１Ｈ－ピロール－３－カルボキサミド（ＨＣ５８－７８）、
ならびにその薬学的に許容される塩、からなる群から選択される化合物。
g. (Z)-N-(3-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl) Piperazin-1-yl)propyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (HC58-38);
h. (Z)-N-(3-(4-(2-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)pentyl)amino)-2-oxoethyl)piperazin-1-yl)propyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole- 3-carboxamide (HC58-75);
i. (Z)-N-(3-(4-(2-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)hexyl)amino)-2-oxoethyl)piperazin-1-yl)propyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole- 3-carboxamide (HC58-76); and j. (Z)-N-(3-(4-(2-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)octyl)amino)-2-oxoethyl)piperazin-1-yl)propyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole- 3-carboxamide (HC58-78),
and pharmaceutically acceptable salts thereof.
JP2021565854A 2019-05-06 2020-05-05 Hetero-bifunctional compound as a degrading agent for HPK1 Pending JP2022531446A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843816P 2019-05-06 2019-05-06
US62/843,816 2019-05-06
PCT/US2020/031527 WO2020227325A1 (en) 2019-05-06 2020-05-05 Heterobifunctional compounds as degraders of hpk1

Publications (2)

Publication Number Publication Date
JP2022531446A JP2022531446A (en) 2022-07-06
JPWO2020227325A5 true JPWO2020227325A5 (en) 2023-05-15

Family

ID=73051660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565854A Pending JP2022531446A (en) 2019-05-06 2020-05-05 Hetero-bifunctional compound as a degrading agent for HPK1

Country Status (6)

Country Link
US (1) US20230022524A1 (en)
EP (1) EP3965824A4 (en)
JP (1) JP2022531446A (en)
CN (1) CN114423463A (en)
CA (1) CA3137916A1 (en)
WO (1) WO2020227325A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117105933A (en) 2018-10-31 2023-11-24 吉利德科学公司 Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
KR102650496B1 (en) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN115605488A (en) * 2020-05-06 2023-01-13 新锐思生物制药股份有限公司（Us） Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
CN117693503A (en) 2021-07-20 2024-03-12 阿斯利康(瑞典)有限公司 Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer
CN118043324A (en) * 2021-07-30 2024-05-14 百济神州有限公司 Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof
WO2023023941A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same
WO2023086399A1 (en) * 2021-11-10 2023-05-19 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
CA3237015A1 (en) * 2021-11-23 2023-06-01 Jian Jin Heterobifunctional compounds as hpk1 degraders
WO2023151559A1 (en) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 Heterocyclic compound, pharmaceutical composition containing same, and anti-tumor use thereof
WO2024017372A1 (en) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 Indolone derivative and use thereof
WO2024027755A1 (en) * 2022-08-05 2024-02-08 杭州中美华东制药有限公司 Protac chimeric compound, preparation method therefor and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN115819417A (en) 2016-09-09 2023-03-21 因赛特公司 Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
AU2017363257B2 (en) * 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
US11541051B2 (en) * 2016-12-08 2023-01-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
JPWO2020227325A5 (en)
JP2007508346A5 (en)
DOP2017000057A (en) PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL-2 FAMILY INHIBITOR
JP2018535999A5 (en)
JP2010507096A5 (en)
JP2012510989A5 (en)
JP2011526616A5 (en)
JP2017502073A5 (en)
RU2012127760A (en) BCL-2-SELECTIVE APOPTOSIS-INDUCING MEDICINES FOR TREATMENT OF CANCER AND IMMUNE DISEASES
JP2013543896A5 (en)
JP2018511587A5 (en)
JP2006519258A5 (en)
JP2004511469A5 (en)
NZ596071A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
JP2004504301A5 (en)
JP2010505809A5 (en)
NO20031833D0 (en) Treatment of gastrointestinal stromal tumors
JP2008523006A5 (en)
RU2010110640A (en) COMPOUNDS AND COMPOSITIONS 5- (4- (HALOGENALCOXY) Phenyl) PYRIMIDIN-2-AMINE AS KINASE INHIBITORS
JP2007519717A5 (en)
JP2007511485A5 (en)
JP2011500679A5 (en)
JP2015509510A5 (en)
AR064302A1 (en) SUBSTITUTE ARILPIRAZOLES
JP2006503081A5 (en)